在SARS-CoV-2中使用辅助治疗:一个随机临床试验
Silvia Gómez-Zorrilla1, Elena Sendra2, Juan Du3
1Infectious Diseases, Hospital del Mar, Barcelona, Spain; Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra, Barcelona, Spain; CIBERINFEC, ISCIII, Spain.
概括
补充剂显著减少了住院COVID-19患者的疾病进展. 这种辅助疗法也显示出更快的临床康复趋势,突出了在治疗病毒感染方面的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 营养科学 营养科学
背景情况:
- 是一种重要的微量元素,对免疫功能至关重要,具有已知的抗病毒和抗炎性质.
- 低血水平与COVID-19患者的不良结果相关.
- 这项研究调查了作为住院COVID-19病例的附加治疗方法的疗效和安全性.
研究的目的:
- 评估补充剂作为住院COVID-19患者的辅助疗法的有效性.
- 评估口服酸在这个患者群体中的安全性.
- 为了确定对疾病进展和临床康复的影响.
主要方法:
- 一个单中心,随机,开放标签试验,涉及住院的COVID-19成年人.
- 参与者在14天内接受了标准护理 (SoC),有或没有口服酸盐 (90毫克/天).
- 主要终点:疾病进展 (ICU入院或死亡);次要终点:康复时间,住院时间,临床改善,炎症标志物和抗体反应.
主要成果:
- 与SOC组 (23.5%) 相比,组 (5.7%) 的疾病进展明显较低.
- 接受治疗的患者的平均恢复时间明显较短 (7.4天 vs 13.1天).
- 在组中观察到更大的WHO规模改善;没有任何不良事件与补充剂有关.
结论:
- 辅助补充剂有效地减少了住院COVID-19患者的疾病进展.
- 治疗显示出加速临床康复的趋势,这表明它在控制病毒性呼吸道感染方面的作用.
- 这些发现支持作为病毒性呼吸道感染治疗剂的潜力.
更多相关视频
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
2.3K
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
9.2K
相关概念视频
01:16Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K